Author: franperez66q@protonmail.com
Bernstein names top water picks as UK and France enter major investment cycle Source link
SpaceX’s record-breaking IPO boosted founder and CEO’s Elon Musk’s personal stake in the company to more than $1 trillion. But he isn’t the only one seeing huge gains from SpaceX’s blockbuster listing. The IPO also minted thousands of new millionaires — and saw stakes of some shareholders surpass the billion-dollar mark.SpaceX’s debut week on the public markets has seen investors scramble to buy into Musk’s lofty ambitions for the company, but cooling sentiment has pared some of those gains over the past couple of days.Earlier in the week, its market cap surpassed Amazon and — briefly — Microsoft. Thursday’s loss,…
The Reform UK leader says he is “disappointed” with his party’s performance in the key by-election. Source link
A man talks on his phone walks past a Jio store in Mumbai, India, 22 March, 2023. Reliance Jio rolls Out 5G Services in 41 More Cities, Network Now Live in 406 Cities in India according to an Indian media report. Nurphoto | Nurphoto | Getty ImagesBillionaire Mukesh Ambani’s Jio Platforms, India’s largest wireless operator and digital service provider, filed draft papers for an initial public offering on Friday.The IPO will see the company issue up to 270 million shares, as per an exchange filing.”The proposed listing of Jio will demonstrate to the world that India can build technology companies…
Admiral shares fall 4% as RBC cuts rating, flags UK motor pricing lag Source link
I will run, I will stand if there’s a leadership contest – PM Source link
Black smoke rises from the area of the Russian oil producer Gazprom Neft’s Moscow oil refinery on the south-eastern outskirts of Moscow on June 18, 2026.- | Afp | Getty ImagesRussia has pledged to carry out frequent and “massive group strikes” against Ukraine shortly after Kyiv launched a barrage of drones on Moscow, triggering a huge explosion in one of the Russian capital’s key oil refineries.Ukrainian forces conducted a large-scale attack against Moscow on Wednesday evening and Thursday, heavily targeting a major oil refinery located on the south-eastern outskirts of the city. Nearly 200 drones were reportedly used in the…
Investing.com — fell 19% to 1,620p today after Israeli hospitality operator formally abandoned its pursuit of the company. Fattal concluded it would not proceed with its indicative £22-per-share cash offer following opposition from Euro Plaza Holdings, which controls approximately 33% of PPHE’s issued share capital. PPHE’s independent committee, established specifically to oversee the takeover process, determined that the Fattal proposal was no longer capable of being delivered in its current form. The decision removed the takeover premium that had supported PPHE’s share price since the bid was first disclosed in late May. The collapse of the Fattal approach leaves PPHE’s…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” said U.S. Trade Representative Jamieson Greer in a statement late Thursday. “I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals,” he said, calling it “a serious step backwards.” In April, Germany proposed overhauling its health insurance system…
Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy.But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to Zealand’s amylin-based medicine, petrelintide, as the next potential driver of the stock, setting it up for an important year ahead.The Copenhagen-listed stock tumbled 23% earlier this month after survodutide, which Zealand has licensed to Boeringer Ingelheim, showed side effects grave enough for 19% of patients to…